Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study

Table 1

Patient characteristics.

Characteristic	No. of patients (%)
No. of patients	40
Median age (range), y	55 (44–69)
Gender
Male	37 (92.5%)
Female	3 (7.5%)
WHO performance status
0	1 (2.5%)
1	30 (75%)
2	9 (22.5%)
Child-Pugh stage
A	28 (70%)
B	12 (30%)
Median AFP (range), ng/mL	450 (3–99500)
AFP >400 ng/mL	31 (77.5%)
Histologic diagnosis of HCC	20 (50%)
Diagnosis of HCC based on Barcelona criteria	20 (50%)
Patients with extrahepatic disease	12 (30%)
Previous treatment
None	15 (37.5%)
Radiofrequency ablation	10 (25%)
Curative surgery	3 (7.5%)
TACE	12 (30%)
Systemic therapy	0